News Xencor, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
19.98 ^USD	+3.90%		+8.71%	-5.89%

04-16	BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating	MT
04-09	Xencor Names Bart Cornelissen as Chief Financial Officer	MT

BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating	04-16	MT
Xencor Names Bart Cornelissen as Chief Financial Officer	04-09	MT
Xencor Appoints Bart Cornelissen as Chief Financial Officer	04-09	BU
Xencor, Inc. Announces CFO Changes	04-09	CI
Xencor Appoints Bart Cornelissen as Senior Vice President	04-09	CI
USTPO Issues Means-Plus-Function Memorandum	03-27	AQ
Transcript : Xencor, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:15 AM	03-14
Xencor Insider Sold Shares Worth $293,519, According to a Recent SEC Filing	03-07	MT
North American Morning Briefing : Fed's Preferred -2-	02-29	DJ
Xencor to Present at Upcoming Investor Conferences	02-28	BU
Wedbush Adjusts Xencor's Price Target to $34 From $36, Keeps Outperform Rating	02-28	MT
Transcript : Xencor, Inc., Q4 2023 Earnings Call, Feb 27, 2024	02-27
Xencor: Q4 Earnings Snapshot	02-27	AQ
Earnings Flash (XNCR) XENCOR Posts Q4 Revenue $44.7M, vs. Street Est of $74.7M	02-27	MT
Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results	02-27	BU
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update	02-20	BU
Treatment Of Antibody Claims In The U.S. After Amgen v. Sanofi	02-19	AQ
Xencor Insider Sold Shares Worth $1,048,743, According to a Recent SEC Filing	02-14	MT
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab	02-06	AQ

No results for this search